TheEdgeResearch
Home / Stocks / XVIPF

Xvivo Perfusion AB (publ) (XVIPF)

OTC Healthcare Medical - Devices
$24.50 ▲ +0.00%
Market Cap
$771.7M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.46
52-Wk Range
16.975-29.48
CEO
Christoffer Rosenblad
Country
SE
Currency
USD

Xvivo Perfusion AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Mölndal, VG, SE. The stock last traded at $24.50, up 0.00% on the session, giving a market capitalisation of $771.7M. On trailing twelve-month figures it carries a trailing P/E of 109.32, a net margin of 9.9%. Its beta of 1.46 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
109.32
Price / Sales
10.81
Price / Book
4.40
EV / EBITDA
51.56
Gross margin
62.8%
Operating margin
12.7%
Net margin
9.9%
Return on equity
Debt / equity
0.06
Current ratio
3.86
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
210
IPO date
2014-07-21
Headquarters
Mölndal, VG, SE
About Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine. The firm specializes in pioneering solutions for the preservation and perfusion of organs, tissues, and cells, essential for successful transplant procedures. With a significant international presence, Xvivo Perfusion operates across diverse markets, including Sweden, the United States, wider North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Among its key product offerings is the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass apparatus designed for normothermic ex vivo lung perfusion (EVLP). Complementing this, the company provides the XPS Disposable Lung Kit, comprising sterile, pre-packaged components required for EVLP, and STEEN Solution, a specialized buffered extracellular fluid used for perfusing isolated donor lungs during the EVLP process. Xvivo also offers Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution crucial for preservation. Other significant products include the XVIVO Silicone Tubing Set for rapid flushing of donor lungs post-procurement; the XVIVO LS and XVIVO Disposable Lung Set, devices engineered for EVLP; and the XVIVO Organ Chamber, a single-use sterile container designed for the temporary storage of isolated lungs prior to their transplantation into a recipient. Additionally, the XVIVO Lung Cannula Set, a sterile, single-use disposable product, is part of their portfolio. Established in 1998, Xvivo Perfusion AB (publ) maintains its headquarters in Gothenburg, Sweden.

Comparable companies

Xvivo Perfusion AB (publ) is most often compared with the following Healthcare names:

AVNBFBJTRFCALZFCLVSFFDMDFFOGCFLBLTFSOLTFSWDCFVBIZF
More research on XVIPF
XVIPF technical analysis XVIPF TheEdge Score Compare against peers
Open full interactive analysis & DCF →